Emergent BioSolutions Inc (EBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Emergent BioSolutions Inc (Emergent) is a biopharmaceutical company focused on developing products to address medical needs and public health threats (PHTs). The company’s solutions help in addressing chemical, biological, radiological, travel health, emerging health crises, nuclear and explosives (CBRNE), emerging infectious diseases, and acute/emergency care. Its major products and services encompass a portfolio of vaccines, nasal sprays, therapeutics, drug-device combination products, and contract development and manufacturing services. The company’s pipeline products include zaire ebolavirus, raxibacumab for anthrax, and others. Emergent's products are utilized by federal and state leaders, community-based organizations, law enforcement, and first responders for applications such as opioid emergency preparedness and medical countermeasures against health threats like botulism, Ebola, smallpox, and anthrax. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Gaithersburg, Maryland, the US.
Emergent BioSolutions Inc Key Recent Developments
May 28, 2026: Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy
May 20, 2026: Emergent BioSolutions to Participate in Upcoming Investor Conferences
Apr 29, 2026: Emergent BioSolutions Partners With Baseball Player Davis Schneider to Raise Awareness of NARCAN Nasal Spray in Canada
Apr 29, 2026: Emergent BioSolutions Secures Multi-Year Manufacturing Agreement With SAB Biotherapeutics to Advance Type 1 Diabetes Candidate SAB-142
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Kyntra Bio Inc - Key Facts
Kyntra Bio Inc - Key Employees
Kyntra Bio Inc - Key Employee Biographies
Kyntra Bio Inc - Major Products and Services
Kyntra Bio Inc - History
Kyntra Bio Inc - Company Statement
Kyntra Bio Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Kyntra Bio Inc - Business Description
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
R&D Overview
Kyntra Bio Inc - Corporate Strategy
Kyntra Bio Inc - SWOT Analysis
SWOT Analysis - Overview
Kyntra Bio Inc - Strengths
Kyntra Bio Inc - Weaknesses
Kyntra Bio Inc - Opportunities
Kyntra Bio Inc - Threats
Kyntra Bio Inc - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Kyntra Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Kyntra Bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Kyntra Bio Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
Jun 11, 2026: Kyntra Bio Presents Roxadustat Data Showing Improved Transfusion Independence Regardless of Ring Sideroblast Status in Lower-Risk Myelodysplastic Syndromes
May 11, 2026: Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Mar 17, 2026: Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 09, 2026: Kyntra Bio to Report Fourth Quarter and Full-Year 2025 Financial Results
Feb 17, 2026: Kyntra Bio to Participate in Upcoming Investor Conferences
Nov 10, 2025: FibroGen Reports Third Quarter 2025 Financial Results
Sep 24, 2025: FibroGen Initiates Phase 2 Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer
Aug 18, 2025: FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
Aug 11, 2025: FibroGen Reports Second Quarter 2025 Financial Results and Business Update
Jun 09, 2025: FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
Section 6 - Appendix
Methodology
Ratio Definitions
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
Kyntra Bio Inc, Key Facts
Kyntra Bio Inc, Key Employees
Kyntra Bio Inc, Key Employee Biographies
Kyntra Bio Inc, Major Products and Services
Kyntra Bio Inc, History
Kyntra Bio Inc, Subsidiaries
Kyntra Bio Inc, Key Competitors
Kyntra Bio Inc, Ratios based on current share price
Kyntra Bio Inc, Annual Ratios
Kyntra Bio Inc, Interim Ratios
Kyntra Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Kyntra Bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Kyntra Bio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Kyntra Bio Inc, Performance Chart (2021 - 2025)
Kyntra Bio Inc, Ratio Charts
Kyntra Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Kyntra Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net